TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT04557449: A PHASE 1/2A STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTI-TUMOR ACTIVITY OF PF-07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID

Sponsor: Pfizer · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 430 pts

Competing Trials Overlap

9 Active Trials

Excess Burn Exposure

$12,474,000

Rescue Site Savings

+$8,223,600

Unlock Full NCT04557449 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04557449 Rescue Dossier →